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amount of rFVIIa used to achieve haemostasis. A Generalized Linear Regression
Model was used to derive the potential cost-offsets of a novel treatment. The net
monetary benefit per bleeding treated of the novel treatment compared to rFVIIa
was estimated using a variety of assumptions on the efficacy of the novel treat-
ment as well as on the valuation of the health benefits. RESULTS: Assuming a
reduction in time to bleeding resolution by 25%, a novel treatment saved €339 per
bleeding compared to rFVIIa. Including the value of the health benefits, whichwere
estimated to €51, the net monetary benefit of the novel treatment was €390 per
bleeding. The results were sensitive to assumptions around the efficacy of the new
treatment but also around the valuation of health benefits.CONCLUSIONS:Anovel
treatment which reduces time to bleeding resolution would entail important
health economic benefits, both in terms of health care cost-offsets and health
benefits. One limitation of cost-effectiveness analyses in hemophilia is the uncer-
tainty around the valuation of short term health benefits.
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BACKGROUND:Themajority of analyses of outcomes related to fertility treatments
are conducted in datasets from fertility centers. To date there has been no estab-
lished methodology for identifying fertility protocols in payer databases.
OBJECTIVES: To identify a methodology for identifying fertility protocols in a na-
tional administrative claims database. METHODS: This retrospective descriptive
study used PharmMetrics, a national managed care dataset. Patients with at least
one prescription for a gonadotropin-releasing hormone agonist (GnRHAg) or an-
tagonist (GnRHAnt) between January 1, 1999 andMay 31, 2009 were selected. Drugs
billed with a National Drug Code were included and were identified using generic
product identifiers. Index date was set as the first pharmacy claim date for a Gn-
RHAg or GnRHAnt. Patients were excluded if no prescription record for FSH existed
in the 7 days pre-index through 60 days post-index and HCG in the 60 day post-
index period. Patients must be eligible for services for 12 months before and after
the index date, which established continuous eligibility for services. Longer eligi-
bility allows assessment of outcomes such as birth rates. The final sample con-
sisted of patientswith an embryo transfer codewithin 60 days of index. Outcome of
delivery codes served as indicators for live birth if they occurredwithin 294 days (42
weeks) after transfer date. RESULTS: Inclusion and exclusion criteria were ap-
plied to patients that had at least one prescription for GnRHAnt or GnRHAg,
resulting in some attrition of sample (880 patients with IVF). The 2-year contin-
uous eligibility requirement accounted for the largest number of patients
removed. CONCLUSIONS:Administrative claims data provide a large sample of IVF
patients, but are limited in some analyses due to a lack clinical details. The pro-
posedmethodology was able to successfully identify IVF treatment cycles and link
these to delivery outcomes for treated patients under real-world conditions.
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OBJECTIVES: Individual domains of multidomain patient-reported outcome in-
struments typically are analyzed independently, without considering inherent de-
pendency of component domains. This report presents an underused modeling
approach that accounts for correlations across time (longitudinal) and correlations
across domains of a multidomain instrument in one integrated model.METHODS:
International Index of Erectile Function (IIEF) data from a double-blind placebo-
controlled trial of fixed-dose sildenafil (50 or 100 mg) in 288 men with erectile
dysfunctionwere used. Standardmethodologywas used for the individual-domain
longitudinal model. This model was then expanded to account for relationships
among domains for the multidomain longitudinal model, performing modeling of
treatment effects on all domains simultaneously. Covariance was constructed by
taking the Kronecker product of an unstructured covariance matrix across do-
mains (modeling covariance across the domains) with an unstructured covariance
matrix across time (modeling covariance across time). Analyses were performed
with Proc Mixed using SAS v9.2. RESULTS: The model was constructed and fitted,
which integrated all IIEF domains simulataneously into one unified multidomain
longitudinal model. Treatment effects for all 5 IIEF domain scores calculated using
individual ormultidomainmodelingwere similar, reflecting the robust application
of IIEF data in this study. CONCLUSIONS: Modeling correlation structure simulta-
neously across domains of amultidomain instrument, as well as across time,more
rigorously addresses the interrelationship between domains and potentially pres-
ents a more accurate estimation of efficacy and statistical inferences. Additional
work with simulations and more empirical evidence are needed to better under-
stand the multidomain longitudinal model.
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OBJECTIVES: Efficiency in health systems is often a matter of concern and differ-
ences on the expected productivity of a given procedure might lead to inefficient
variations in the performance of such interventions. Health economics literature
has extensively revisited the topic of variations in health care using multivariate
models to predict variation across geographic regions. The clustering effect of fa-
cilities (as a functional unit), however. has not been described before. This analysis
examines the extent to which facilities explain geographic variation in health care.
METHODS: A set of individual data on all births from a Contributory-Regimen
insurer in Colombia was assessed. We performed a multilevel logistic regression
model, taking hospitals as the clustering variable. In addition, we included an
alternative variance decomposition specification to estimate the attributable effect
of geographic region on the variability across hospitals. We used a set of variables
includingmother education and income, physician fees, and complications during
pregnancy to control for in this analysis. RESULTS:Our results reveal that hospitals
account for 20% of variation on the probability of performing cesarean sections.
Geographic area only explains one-third of the variance attributable to the hospi-
tal. In addition, physician fees (0.077; SE 0.023), mother’s income (0.070; SE 0.014)
and superior education in mothers (0.299; SE 0.107). This supports the effect of
mother and physician preferences on variations. CONCLUSIONS: This paper con-
tributes to previous research by using amultilevel model approach and by defining
hospitals as cluster. We found a strong effect of hospitals on determining varia-
tions. In addition, we found how supply-side factors such as physician fees and
demand-side factors (proxies for preferences) such as mother’s education and in-
come are affecting variations across hospitals and regions. The effect of facility as
well as individual-level variables should be taken into account when researching
on variations in health care.
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OBJECTIVES: The linguistic validation and cognitive debriefing of PROs are now
well documented and routinely usedwithin the pharmaceutical industry to ensure
that the translated instruments are conceptually equivalent to their sources. In-
creasingly, new adjustments are being developed to further customize these pro-
cesses according to the special needs of the instrument and target culture. This
paper seeks to enumerate the challenges faced when debriefing questionnaires of
an embarrassing, and potentially offensive, nature and recommends the use of a
specialized methodology to make respondents more comfortable during this
process. METHODS: To establish guidelines for debriefing PROs of a sensitive na-
ture, subject feedback from previous ED questionnaire debriefing reports was ex-
amined. The subjects that expressed the most discomfort during the debriefing
process resided in India, Africa, and the Middle East. Additionally, older subjects
and subjects with lower levels of education were more likely to express reserva-
tions. For this study, we collaboratedwith translators from each of these regions to
determine a list of measures that can be taken to help ensure that subjects feel
comfortable enough to provide reliable feedback within the interview setting.
RESULTS: The goal of any cognitive debriefing session is to adequately test the
translated questionnaire while maintaining the cultural sensitivities of the target
country. Recommended considerations include: assigning an interviewer of the
same sex as the subject, performing a specialized training session with interview-
ers that reviews subjects’ boundaries and strategies for effective probing, sending
subjects an introductory note that emphasizes confidentiality prior to the inter-
view, conducting interviews via telephone rather than in-person, and debriefing
questionnaires via a web-based device. CONCLUSIONS: For some cultures, cogni-
tively debriefing PRO questionnaires of a sensitive nature places added burden on
respondents. Evidence suggests that additional considerations should be exercised
during debriefing to respect subjects’ cultural boundaries.
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OBJECTIVES: To describe reporting rates and characteristics of vaccine-associated
GBS reports in the Vaccine Adverse Event Reporting System (VAERS) over a two-
decade period.METHODS:Adverse event reports submitted to VAERS from January
1990 to November 2009 are utilized to conduct a retrospective pharmacovigilance
analysis by calculating the proportional reporting ratios (PRR) and corresponding
95% confidence intervals (CI) for vaccine-GBS event pairs. RESULTS: One thousand
and 259 reports of vaccine-associated GBS are identified for 37 vaccines. Themean
age of patients experienced GBS after vaccination was 31 years; 51% of patients
were females. Majority of the reports were for influenza (FLU) (791) and hepatitis B
(HEP) virus vaccines (103). Reports for human papillomavirus quadrivalent (HPV4),
meningococcal conjugate (MNQ), and measles/mumps/rubella (MMR) virus vac-
cines accounted for 37, 36, and 34 reports, respectively. Death, disability and hos-
pitalization among the serious GBS outcomes were correspondingly reported in 36
(2.9%), 199 (15.8%), and 963 (76.4%) reports. Most of these outcomes were in FLU
reports. The average postvaccination GBS onset delay was 3.5 weeks; ranging from
2.3weeks for FLU to 8.1weeks forMNQ. About 79% and 12% of GBS reports included
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zero, and 2-4 concomitant vaccines, respectively. About 49% of the reports indi-
cated that patients were on concurrentmedications at the time of vaccination, yet;
only 12% of the reports stated that the patients were having coexisting illnesses at
vaccination time. Compared to other vaccines, FLU and MNQ vaccines showed
significantly higher PRR values (10.5, 95%CI 9.4-11.8), (4.7, 95%CI 3.4-6.6).
CONCLUSIONS: It can be postulated that some vaccines are associated with GBS,
especially FLU and MNQ vaccines; underscoring the importance of monitoring pa-
tients for postvaccination signs and symptoms of GBS. While healthcare profes-
sionals are expected to promote vaccination, they should also continue to report
vaccine-associated adverse events to vaccine safety monitoring systems, e.g.
VAERS.
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OBJECTIVES: MRSA skin infections are associated with high morbidity and cost.
Little is known about real-world daptomycin effectiveness in relevant subpopula-
tions. We evaluated outcomes including time to response, duration of antibiotic
therapy, and antibiotic-related hospital length of stay (AR-LOS) in subpopulations
of patients with MRSA skin infections treated with daptomycin. METHODS: Pa-
tients with MRSA skin infections were identified in a retrospective, multicenter,
observational registry describing safety and real-world effectiveness of patients
treated with daptomycin (Cubicin Outcomes Registry and Experience; CORE®). In-
vestigators assessed patient outcome at the end of daptomycin therapy. Subpopu-
lations of interest included those with reduced vancomycin susceptibility (MIC
2mcg/mL), the elderly, diabetics, and those with renal dysfunction. RESULTS: A
total of 137 patients were identified: 53% male, 33% 65yo, 31% diabetic, 6% CrCL
30ml/min. Of patients with vancomycin MICs, 14% were2. Median daptomycin
dose was 6mg/kg; 82% had prior antibiotics (66% of which was vancomycin). Suc-
cess occurred in 94% overall, and was 100% in first-line daptomycin, 93% as second
line. Time to clinical response ranged from 2-4 days with a median of 3 days for
both first and second-line therapy. Median AR-LOS tended to be greater among
subpopulations: those with vancomycin MIC2 [5 vs. 4 days],65 yo [6 vs. 5 days],
diabetics [6 vs. 4 days], and those with CrCL 30 [8 vs. 5 days], compared to those
without each respective condition. Total treatment duration (inpatient and outpa-
tient days) ranged from 7-13 days, depending on clinical subgroup. 11/137 patients
(8.3%) had AEs possibly related to daptomycin; discontinuation due to AEwas 5.8%.
CONCLUSIONS:This evaluation of relevant patient populations providesmeaning-
ful information about real-world effectiveness of daptomycin-treated MRSA skin
infections. AR-LOSwas longer in evaluated subgroups, particularly thosewith CrCL
30ml/min. Additional real-world evaluations, including comparative effective-
ness studies are warranted to further evaluate relevant outcomes in various sub-
populations with MRSA skin infections.
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OBJECTIVES: In diabetes mellitus patients, infected diabetic foot represents 20% of
hospitalizations. In order tominimize health services cost its important to evaluate
which antimicrobial agent could be the best option. The aim of this study was to
conduct a meta-analysis of randomized clinical trials (RCTs) to determine effec-
tiveness and safety of linezolid in the treatment of infected diabetic foot in com-
parisonwith other antimicrobial agents.METHODS:All meta-analysis estimations
were performedwith RCTs based on trials enrolling patientswithmild tomoderate
diabetic foot infections treated with one antimicrobial agent. Effectiveness was
assessed through clinical efficacy (cure/healing); safety and microbiological end-
point indicators. RCTs were searched in December 2009 in Medline, EMBASE, and
the Cochrane Collaboration. Two independent reviewers identified abstracts, se-
lected full articles, and extracted the data. Odds ratios (OR) and weighted mean
differences were calculated. Random effects models were employed in the analy-
seswith RevMan v.5.0 software.RESULTS: 1,528 studieswere reviewed and 19 trials
were finally selected. 13/19 RCTs assessed patients with diabetes mellitus and 6/19
patients with soft tissue infections. Regarding clinical results: linezolid was as
effective as ciproflaxin, ofloxacin and ertapenem; although with higher clinical
efficacy compared to piperacillin/tazobactam (OR 0.52; IC95% 0.340.77 p0.001),
ampicillin/sulbactam (OR 0.40; CI95% 0.270.61 p0.001) and daptomicin (OR 0.45;
IC95% 0.22-0.90 p0.02). Regarding microbiological efficacy, similar results were
estimated (Staph. aureus eradication); however, ertapenem showed a better result
(OR 2.60; CI95% 1.11–6.07 p0.03) than linezolid. Nevertheless, linezolid exhibited
superiority against oxiflacin (OR 0.36; CI95% 0.20-0.65, p0.0006). Frequency of
adverse events was similar in all RCTs. CONCLUSIONS: Currently, little published
evidence exists to define which antimicrobial agent would be the optimum drug
for mild to moderate infected diabetic foot patients. Though, linezolid demon-
strated to be an effective and safe treatment using clinical and microbiological
endpoints.
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OBJECTIVES: In patients with HIV-1, the reduction in RNA copies associated to
treatment has shown a better survival rate. The Highly Active Antiretroviral Ther-
apy (HAART) is the recommended treatment for those patients. As a chronic dis-
ease, the adherence to treatment and adverse effects plays a mayor role. The
objective was to evaluate the efficacy and safety of the combination Efavirenz,
Tenofovir and Emtricitabine (EFV/TDF/FTC) administred once daily compared to
the available treatment combinations in Mexico. METHODS: We conducted a
systematic review using the Cochrane guidelines of randomized clinical trials in
PubMed, EMBASE, LILACS AND Artemisa to compare EFV/TDF/FTC, TDF/
FTCATV/r, TDF/FTCLPV/r, TDF/FTCSQV/r, TDF/FTCFPV/r, ABC/3TCEFV,
ABC/3TCLPV/r, ZDV/3TC/EFV, ZDV/3TCLPV/r in naïve adult patients with
HIV-1 infection. The main outcome variables were RNA HIV-1 copies less than
50/mm3 at 48 and 96 weeks, and grade 2-4 adverse effects at 48 weeks. We used
a random model effects for the pooled analysis. RESULTS: We included 13 arti-
cles, 9 at 48weeks and 4 at 96weeks. The armswere grouped by the three elements
of HAART. The combination EFV/TDF/FTC was the most frequently used (4 and 2
studies at 48 and 96weeks). At 48 and 96weeks the pooled probabilities to have50
RNA copies/ml for EFV/TDF/FTC were 0.784 (CI95%:0.736-0.825; n962) and 0.734
(0.601-0.835; n514); TDF/FTCLPV/r 0.694(0.611-0.766; n958) and 0.633(0.528-
0.726; n788); TDF/FTCATV/r 0.848(0.652-0.943; n488) and 0.743(0.700-0.782;
n440) respectively. The 2-4 grade adverse events rates at 48 weeks were for EFV/
TDF/FTC 0.225(0.074-0.513; n1129); for ABC/3TCEFV 0.316(0.279-0.354; n589); and
for ZDV/3TC/EFV 0.634(0.573-0.691; n254). At 48 weeks the discontinuation rate for
EFV/TDF/FTCwas 0.051(n536); TDF/FTCLPV/r 0.071(n170); and for ZDV/3TCEFV
0.079(n349); the lowestwas TDF/FTCSQV 0.028(n176).CONCLUSIONS: The com-
bination EFV/TDF/FTC is themost studied combination and is clinically effective at
48 and 96 weeks, with good safety profile. The administration once a day improves
the adherence to treatment.
PIN5
THE PREVALENCE AND ECONOMIC BURDEN OF HEPATITIS C VIRUS INFECTION
IN CANADA AND LATIN AMERICA: A SYSTEMATIC REVIEW
Szabo SM1, Donato BM2, Yuan Y3, Bibby M1, Jimenez-Mendez R4, Levy AR1
1Oxford Outcomes Ltd., Vancouver, BC, Canada, 2Bristol-Myers Squibb, Wallingford, CT, USA,
3Bristol-Myers Squibb, Plainsboro, NJ, USA, 4University of British Columbia, Vancouver, BC,
Canada
OBJECTIVES:The global prevalence of hepatitis C virus (HCV) infection is estimated
at over 300million persons. Despite stable prevalence, the economic burden in the
United States (US) is projected to double over the next decade. Less is known,
however, for the rest of the Americas. These epidemiologic and economic data are
critical for decision-makers to project the impacts of HCV treatments. The objec-
tive of this study was to synthesize literature-based estimates of the prevalence
and economic burden of HCV fromCanada,Mexico, Brazil, Argentina, Peru, Colom-
bia, and Venezuela.METHODS: A systematic review was conducted in September
2010 to determine the a) prevalence, and b) resultant economic burden, of HCV.
Two independent reviewers extracted data from articles meeting the inclusion
criteria: from EMBASE, Medline, or the Cochrane databases; focusing on general
population estimates from the target countries; and published since the year 2000.
RESULTS: The search strategy identified 280 abstracts; eight provided general pop-
ulation prevalence estimates. In Brazil, the prevalencewas estimated at 1.4% in Sao
Paulo, and 3.6% in the state of Para. Canadian national surveillance programs es-
timated HCV prevalence at 0.8%; with provincial estimates from 1.3% to 2.0%. Mex-
ican estimates ranged from 0.7% to 2.0%; the national health survey reported a
prevalence of 1.4%. No prevalence estimates were identified for the remaining
countries. Only one study (from Canada) assessed the overall economic burden.
Despite a predicted 14% decrease in prevalence, HCV-related costs were projected
to increase by over 50%, to 158 million dollars annually by 2040. CONCLUSIONS:
HCV prevalence estimates varied from 0.8% to 3.6%, from general population based
studies from Canada, Mexico, and Brazil. Canadian data suggest the economic
burden of HCV is large, and increasing. While these data are useful for decision-
makers, the paucity of data for South America highlights a substantial knowledge
gap.
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In 1996 theUSAdvisoryCommittee on ImmunizationPractices recommendedadmin-
istration of hepatitis A vaccine for those at risk of infection. In 2005, the recommen-
dation was extended to all children and at risk adults. Comprehensive data on hepa-
titis A incidence in amanaged care population has not been evaluated. OBJECTIVES:
To evaluate the incidence of hepatitis A in amanaged care population from 2005 to
2008. METHODS: This was an observational, retrospective cohort study utilizing
medical and pharmacy claims data from January 1, 2005 through December 31,
2008 from the HealthCore Integrated Research Database (HIRDSM). The index date
was defined as date of first diagnostic claim for hepatitis Awithin the intake period.
Patients included were at least 18 years old and had continuous eligibility for at
least 12 months prior to and after index date. RESULTS: A total of 7674 patients
were diagnosed with hepatitis A (51.1% male). Annual incidence was similar for
A114 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 1 – A 2 1 4
